Editorial Board

Biography

Dr. Stephen L. Chan

Department of Clinical Oncology, The Chinese University of Hong Kong, China
Email: [email protected]

Qualifications

MBBS (HKU); MRCP (UK), FRCP (Edin), FHKCP, FHKAM (Medicine)

Publications (Selected)

  1. Chan AW, Tong JH, Chan SL, Lai PB, To KF. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology. 2014; in press. DOI: 10.1111/his.12342 (Impact factor: 2.857)
  2. Yu SC, Hui JW, Hui EP, Chan SL, Lee KF, Mo F, Wong J, Ma B, Lai P, Mok T, Yeo W. Unresectable Hepatocellular Carcinoma: Randomized Controlled Trial of Transarterial Ethanol Ablation versus Transcatheter Arterial Chemoembolization. Radiology. 2014. 270: 607-20. (Impact factor: 6.339)
  3. Chan KC, Jiang P, Chan CW, Sun K, Wong J, Hui EP, Chan SL, Chan WC, Hui DS, Ng SS, Chan HL, Wong CS, Ma BB, Chan AT, Lai PB, Sun H, Chiu RW, Lo YM. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci USA. 2014; 110: 18761-8. (Impact factor: 9.737)
  4. Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong W, Wilson S, Johnson BF, Edwards C, Stocken DD, Rickinson AB, Steven NM, Chan AT. Phase 1 trial of recombinant Modified Vaccinia Ankara (MVA) encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res 2013;73:1676-1688. (Impact Factor: 8.650)
  5. Zhou Q, Wong CH, Lau CP, Hui CW, Lui VW, Chan SL, Yeo W.  Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and in Microtubule-Stabilization in Hepatocellular Carcinoma. Int J Hepatol. 2013. Doi:  10.1155/2013/103830  (Indexed Journal)
  6. Poon MC, Leung CM, Chan SL, Lee KM, Lee WY, Chau RM, Wong SC, Kung SW, Kam MK, Yu BK, Chan AT. Efficacy and toxicity of intensity modulated radiation therapy (IMRT) for prostate cancer in Chinese patients. Hong Kong Med J. 2013. In press (Indexed Journal)
  7. Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, Wong J, Siu SS, Chan WC, Chan SL, Chan AT, Lai PB, Chiu RW, Lo YM. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013; 59:211-224. (Impact Factor: 7.149)
  8. Li CH, To KF, Tong JH, Xiao Z, Xia T, Lai PB, Chow SC, Zhu YX, Chan SL, Marquez VE, Chen Y. Enhancer of Zeste Homolog 2 Silences miR-218 in Human Pancreatic Ductal Adenocarcinoma Cells by Inducing Formation of Heterochromatin. Gastroenterology 2013;144:1086-1097. (Impact Factor: 12.821)
  9. Ma BB, Kam MK, Leung SF, Hui EP, King AD, Chan SL, Mo F, Loong H, Yu BK, Ahuja A, Chan AT. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol 2012; 23:1287-1292. (Impact Factor: 7.384)
  10. Loong HH, Ma BB, Leung SF, Mo F, Hui EP, Kam MK, Chan SL, Yu BK, Chan AT. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol 2012;104:300-304. (Impact Factor: 4.520)
  11. Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. Biochem Pharmacol. 2012; 83:1146-1158 (Impact Factor: 4.576)
  12. Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, Hui EP, Jeung HC, Roh JK, Yu SC, To KF, Tao Q, Ma BB, Chan AW, Tong JH, Erlichman C, Chan AT, Goh BC. Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol., 2012; 30:3361-3367. (Impact Factor: 18.038)
  13. Hui EP, Ma BB, King AD, Mo F, Chan SL, Kam MK, Loong HH, Ahuja AT, Zee BC, Chan AT. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol 2011; 22:1280-1287. (Impact Factor: 7.384)
  14. Abou-Alfa GK, Chan SL, Lin CC, Chiorean EG, Holcombe RF, Mulcahy MF, Carter WD, Patel K, Wilson WR, Melink TJ, Gutheil JC, Tsao CJ. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2011;68:539-545. (Impact Factor: 2.795)
  15. MA BB, Chan SL, Ho WM, Lau W, Mo F, Hui EP, Chan C, Poon A, Dattatray RD, Wong SC, To KF, King AD, Ahuja A, Chan AT. Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: Correlation With Serum Amphiregulin and Transforming Growth Factor Alpha. Cancer. 119: 4145-53. (Impact Factor: 5.201)
  16. Ma BB, Sung F, Tao Q, Poon FF, Lui VW, Yeo W, Chan SL, Chan AT. The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs. 2010; 28:107-114. (Impact Factor: 3.498)
  17. Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat. 2009; 113:529-535. (Impact Factor: 4.469)
  18. Ma BB, Hui EP, Wong SC, Tung SY, Yuen KK, King A, Chan SL, Leung SF, Kam MK, Yu BK, Zee B, Chan AT. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma-correlation with excision repair cross-complementing-1 polymorphisms. Ann Oncol. 2009; 20:1854-1859. (Impact Factor: 7.384)
  19. Wong N, Yeo W, Wong WL, Wong NL, Chan KY, Mo FK, Koh J, Chan SL, Chan AT, Lai PB, Ching AK, Tong JH, Ng HK, Johnson PJ, To KF.TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer. 2009; 124:644-652. (Impact factor: 6.198)
  20. Chan HLY, Tse CH, Mo F, Koh J, Wong VWS, Wong GLH, Chan SL, Yeo W, Sung JJY, Mok TSK. High Viral Load And Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk Of Hepatocellular Carcinoma. J Clin Oncol 2008; 26:177-182. (Impact Factor: 18.038)
  21. Yeo W, Mo FK, Chan SL, Leung NW, Hui P, Lam WY, Mok TS, Lam KC, Ho WM, Koh J,Tang JW, Chan AT, Chan PK. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology. 2007; 45:1382-1389. (Impact factor: 12.003)
  22. Yeo W, Mo FK, Koh J, Chan AT, Leung T, Hui P, Chan L, Tang A, Lee JJ, Mok TS, Lai PB, Johnson PJ, Zee B. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol. 2006; 17:1083-1089. (Impact Factor: 7.384)